Literature DB >> 22334121

Dose-related modulation of event-related potentials to novel and target stimuli by intravenous Δ⁹-THC in humans.

Deepak Cyril D'Souza1, Daniel J Fridberg, Patrick D Skosnik, Ashley Williams, Brian Roach, Nagendra Singh, Michelle Carbuto, Jacqueline Elander, Ashley Schnakenberg, Brian Pittman, R Andrew Sewell, Mohini Ranganathan, Daniel Mathalon.   

Abstract

Cannabinoids induce a host of perceptual alterations and cognitive deficits in humans. However, the neural correlates of these deficits have remained elusive. The current study examined the acute, dose-related effects of delta-9-tetrahydrocannabinol (Δ⁹-THC) on psychophysiological indices of information processing in humans. Healthy subjects (n=26) completed three test days during which they received intravenous Δ⁹-THC (placebo, 0.015 and 0.03 mg/kg) in a within-subject, double-blind, randomized, cross-over, and counterbalanced design. Psychophysiological data (electroencephalography) were collected before and after drug administration while subjects engaged in an event-related potential (ERP) task known to be a valid index of attention and cognition (a three-stimulus auditory 'oddball' P300 task). Δ⁹-THC dose-dependently reduced the amplitude of both the target P300b and the novelty P300a. Δ⁹-THC did not have any effect on the latency of either the P300a or P300b, or on early sensory-evoked ERP components preceding the P300 (the N100). Concomitantly, Δ⁹-THC induced psychotomimetic effects, perceptual alterations, and subjective 'high' in a dose-dependent manner. Δ⁹-THC -induced reductions in P3b amplitude correlated with Δ⁹-THC-induced perceptual alterations. Lastly, exploratory analyses examining cannabis use status showed that whereas recent cannabis users had blunted behavioral effects to Δ(9)-THC, there were no dose-related effects of Δ⁹-THC on P300a/b amplitude between cannabis-free and recent cannabis users. Overall, these data suggest that at doses that produce behavioral and subjective effects consistent with the known properties of cannabis, Δ⁹-THC reduced P300a and P300b amplitudes without altering the latency of these ERPs. Cannabinoid agonists may therefore disrupt cortical processes responsible for context updating and the automatic orientation of attention, while leaving processing speed and earlier sensory ERP components intact. Collectively, the findings suggest that CB1R systems modulate top-down and bottom-up processing.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22334121      PMCID: PMC3358754          DOI: 10.1038/npp.2012.8

Source DB:  PubMed          Journal:  Neuropsychopharmacology        ISSN: 0893-133X            Impact factor:   7.853


  85 in total

1.  Ultrasensitive measurement of delta-9-tetrahydrocannabinol with a high energy dynode detector and electron-capture negative chemical-ionization mass spectrometry.

Authors:  L M Shaw; J Edling-Owens; R Mattes
Journal:  Clin Chem       Date:  1991-12       Impact factor: 8.327

2.  Early and middle latency evoked potentials in medically and psychiatrically normal daily marihuana users: a paucity of significant findings.

Authors:  G Patrick; J J Straumanis; F A Struve; M J Fitz-Gerald; J E Manno
Journal:  Clin Electroencephalogr       Date:  1997-01

3.  Electrical signs of selective attention in the human brain.

Authors:  S A Hillyard; R F Hink; V L Schwent; T W Picton
Journal:  Science       Date:  1973-10-12       Impact factor: 47.728

4.  Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex.

Authors:  S M Eggan; D S Melchitzky; S R Sesack; K N Fish; D A Lewis
Journal:  Neuroscience       Date:  2010-06-11       Impact factor: 3.590

5.  The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories.

Authors:  Michelle Carbuto; R Andrew Sewell; Ashley Williams; Kim Forselius-Bielen; Gabriel Braley; Jacqueline Elander; Brian Pittman; Ashley Schnakenberg; Savita Bhakta; Edward Perry; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Psychopharmacology (Berl)       Date:  2011-08-16       Impact factor: 4.530

Review 6.  Role of endogenous cannabinoids in synaptic signaling.

Authors:  Tamas F Freund; Istvan Katona; Daniele Piomelli
Journal:  Physiol Rev       Date:  2003-07       Impact factor: 37.312

7.  Neurophysiological Distinction between Schizophrenia and Schizoaffective Disorder.

Authors:  Daniel H Mathalon; Ralph E Hoffman; Todd D Watson; Ryan M Miller; Brian J Roach; Judith M Ford
Journal:  Front Hum Neurosci       Date:  2010-01-29       Impact factor: 3.169

8.  Auditory event-related potentials (P3) and cognitive performance in recreational ecstasy polydrug users: evidence from a 12-month longitudinal study.

Authors:  Susana de Sola; Thais Tarancón; Jordi Peña-Casanova; Josep María Espadaler; Klaus Langohr; Sandra Poudevida; Magí Farré; Antonio Verdejo-García; Rafael de la Torre
Journal:  Psychopharmacology (Berl)       Date:  2008-06-26       Impact factor: 4.530

9.  Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers.

Authors:  Patrik Roser; Georg Juckel; Johannes Rentzsch; Thomas Nadulski; Jürgen Gallinat; Andreas M Stadelmann
Journal:  Eur Neuropsychopharmacol       Date:  2008-06-10       Impact factor: 4.600

10.  P300 responses to novel auditory stimuli in hospitalized schizophrenic patients.

Authors:  E L Merrin; T C Floyd
Journal:  Biol Psychiatry       Date:  1994-10-15       Impact factor: 13.382

View more
  41 in total

Review 1.  The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis.

Authors:  Britta Hahn
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

2.  GABA Deficits Enhance the Psychotomimetic Effects of Δ9-THC.

Authors:  Rajiv Radhakrishnan; Patrick D Skosnik; Jose Cortes-Briones; R Andrew Sewell; Michelle Carbuto; Ashley Schnakenberg; John Cahill; Fred Bois; Handan Gunduz-Bruce; Brian Pittman; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Neuropsychopharmacology       Date:  2015-03-02       Impact factor: 7.853

Review 3.  Neurotoxicology Syndromes Associated with Drugs of Abuse.

Authors:  Rachel A Caplan; Jonah P Zuflacht; Jed A Barash; Corey R Fehnel
Journal:  Neurol Clin       Date:  2020-11       Impact factor: 3.806

4.  Attentional dysfunction in abstinent long-term cannabis users with and without schizophrenia.

Authors:  Johannes Rentzsch; Ada Stadtmann; Christiane Montag; Hagen Kunte; Doris Plöckl; Rainer Hellweg; Jürgen Gallinat; Golo Kronenberg; Maria Christiane Jockers-Scherübl
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2015-07-17       Impact factor: 5.270

5.  Brain Mapping-Based Model of Δ(9)-Tetrahydrocannabinol Effects on Connectivity in the Pain Matrix.

Authors:  Carmen Walter; Bruno G Oertel; Lisa Felden; Christian A Kell; Ulrike Nöth; Johannes Vermehren; Jochen Kaiser; Ralf Deichmann; Jörn Lötsch
Journal:  Neuropsychopharmacology       Date:  2015-10-30       Impact factor: 7.853

Review 6.  Medical and recreational marijuana: commentary and review of the literature.

Authors:  Samuel T Wilkinson
Journal:  Mo Med       Date:  2013 Nov-Dec

7.  Effects of 20 mg oral Δ(9) -tetrahydrocannabinol on the olfactory function of healthy volunteers.

Authors:  Carmen Walter; Bruno G Oertel; Dagmar Ludyga; Alfred Ultsch; Thomas Hummel; Jörn Lötsch
Journal:  Br J Clin Pharmacol       Date:  2014-11       Impact factor: 4.335

8.  Impact of Cannabis Use on the Development of Psychotic Disorders.

Authors:  Samuel T Wilkinson; Rajiv Radhakrishnan; Deepak Cyril D'Souza
Journal:  Curr Addict Rep       Date:  2014-06-01

9.  The psychosis-like effects of Δ(9)-tetrahydrocannabinol are associated with increased cortical noise in healthy humans.

Authors:  Jose A Cortes-Briones; John D Cahill; Patrick D Skosnik; Daniel H Mathalon; Ashley Williams; R Andrew Sewell; Brian J Roach; Judith M Ford; Mohini Ranganathan; Deepak Cyril D'Souza
Journal:  Biol Psychiatry       Date:  2015-03-30       Impact factor: 13.382

10.  Neural correlates of performance monitoring in chronic cannabis users and cannabis-naive controls.

Authors:  Daniel J Fridberg; Patrick D Skosnik; William P Hetrick; Brian F O'Donnell
Journal:  J Psychopharmacol       Date:  2013-02-20       Impact factor: 4.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.